152 related articles for article (PubMed ID: 8978298)
21. Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines.
Klampfer L; Cammenga J; Wisniewski HG; Nimer SD
Blood; 1999 Apr; 93(7):2386-94. PubMed ID: 10090950
[TBL] [Abstract][Full Text] [Related]
22. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
[TBL] [Abstract][Full Text] [Related]
23. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins.
Konopleva M; Tari AM; Estrov Z; Harris D; Xie Z; Zhao S; López-Berestein G; Andreeff M
Blood; 2000 Jun; 95(12):3929-38. PubMed ID: 10845930
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
[TBL] [Abstract][Full Text] [Related]
25. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
26. Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells.
Efferth T; Fabry U; Glatte P; Osieka R
J Cancer Res Clin Oncol; 1995; 121(11):648-56. PubMed ID: 7593128
[TBL] [Abstract][Full Text] [Related]
27. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.
Coustan-Smith E; Kitanaka A; Pui CH; McNinch L; Evans WE; Raimondi SC; Behm FG; Aricò M; Campana D
Blood; 1996 Feb; 87(3):1140-6. PubMed ID: 8562940
[TBL] [Abstract][Full Text] [Related]
28. Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2.
Hedley DW; McCulloch EA
Leukemia; 1996 Jul; 10(7):1143-9. PubMed ID: 8683994
[TBL] [Abstract][Full Text] [Related]
29. Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML.
Lehmann S; Bengtzen S; Broberg U; Paul C
Leuk Res; 2000 Jan; 24(1):19-25. PubMed ID: 10634641
[TBL] [Abstract][Full Text] [Related]
30. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
31. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.
Faderl S; Harris D; Van Q; Kantarjian HM; Talpaz M; Estrov Z
Blood; 2003 Jul; 102(2):630-7. PubMed ID: 12663443
[TBL] [Abstract][Full Text] [Related]
32. Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia.
Deng G; Lane C; Kornblau S; Goodacre A; Snell V; Andreeff M; Deisseroth AB
Mol Med; 1998 Mar; 4(3):158-64. PubMed ID: 9562974
[TBL] [Abstract][Full Text] [Related]
33. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
Batova A; Shao LE; Diccianni MB; Yu AL; Tanaka T; Rephaeli A; Nudelman A; Yu J
Blood; 2002 Nov; 100(9):3319-24. PubMed ID: 12384433
[TBL] [Abstract][Full Text] [Related]
34. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117).
Blair A; Sutherland HJ
Exp Hematol; 2000 Jun; 28(6):660-71. PubMed ID: 10880752
[TBL] [Abstract][Full Text] [Related]
35. PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism.
Banker DE; Cooper JJ; Fennell DA; Willman CL; Appelbaum FR; Cotter FE
Leuk Res; 2002 Jan; 26(1):91-106. PubMed ID: 11734307
[TBL] [Abstract][Full Text] [Related]
36. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
[TBL] [Abstract][Full Text] [Related]
37. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.
Konopleva M; Konoplev S; Hu W; Zaritskey AY; Afanasiev BV; Andreeff M
Leukemia; 2002 Sep; 16(9):1713-24. PubMed ID: 12200686
[TBL] [Abstract][Full Text] [Related]
38. Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells.
Hu ZB; Minden MD; McCulloch EA
Leukemia; 1995 Oct; 9(10):1667-73. PubMed ID: 7564507
[TBL] [Abstract][Full Text] [Related]
39. Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy.
Hu ZB; Minden MD; McCulloch EA
Leukemia; 1996 Mar; 10(3):410-6. PubMed ID: 8642855
[TBL] [Abstract][Full Text] [Related]
40. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia.
Niitsu N; Higashihara M; Honma Y
Exp Hematol; 2002 Nov; 30(11):1273-82. PubMed ID: 12423680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
